PLC Systems Inc. (AMEX:PLC) announced today that it will defer the commencement of the U.S. pivotal trial of its RenalGuard™ System in the prevention of Contrast-Induced Nephropathy (CIN). The company continues to support the investigator-sponsored clinical trial now ongoing in Milan, Italy as well as the limited market launch of RenalGuard in Europe, which began in the first quarter of this year, both of which are focused on the CIN prevention market.PLC Systems was mentioned earlier in our Franklin Industry series
Wednesday, July 23, 2008
Thursday, April 3, 2008
Franklin, MA - PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, announced recently that it has entered into a 3-year exclusive agreement with Artech s.r.l., Cavezzo, Italy for distribution of its RenalGuard System into Italy. Artech is one of Italy's leading distributors of interventional cardiology-related medical devices, doing business with most of Italy's major interventional cardiology centers. Artech will target early adopters who recognize the benefits of utilizing the unique fluid balancing capabilities of RenalGuard System in a cath lab setting during cardiovascular imaging procedures for patients at higher risk of Contrast-Induced Nephropathy (CIN).
Read the full announcement here.
Read the December news here.
Sunday, December 23, 2007
FRANKLIN, MA, December 21, 2007 --- PLC Systems Inc. (AMEX:PLC) announced today that it has received the CE Mark Certificate for its RenalGuard System™, clearing the way for the Company to begin its initial launch of the product in the European Union. The Company expects to initiate a limited launch of RenalGuard™ in the first quarter of 2008 in Italy, targeting early adoptors who recognize the benefits of utilizing the unique fluid balancing capabilities of the RenalGuard System in a cath lab setting during cardiovascular imaging procedures for patients at higher risk of Contrast-Induced Nephropathy (CIN).
Read the remainder of this press release here.
About PLC Medical
PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Mass., PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. CO2 TMR offers a treatment option for angina patients who suffer from severe coronary artery disease. The CO2 Heart Laser is the world's first TMR angina relief device cleared for commercial distribution by both the U.S. Food and Drug Administration and Japanese Ministry of Health, Labor and Welfare, and to obtain a CE Mark for European distribution.
PLC Medical is located at 10 Forge Park.
The PLC Medical web site can be found here.